Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00115778 · ClinicalTrials.gov registry record · Phase 2

Intravenous Immunoglobulin (IVIG) in Lung Transplantation

A Phase 2 study of Lung Transplantation and Hypogammaglobulinemia, sponsored by Columbia University.

Completed
Registry status
Phase 2
Development phase
11
Enrollment target
1
Study location

NCT00115778: Completed Phase 2 study of Lung Transplantation and Hypogammaglobulinemia, sponsored by Columbia University.

NCT00115778 is a Phase 2 study of Lung Transplantation and Hypogammaglobulinemia that has completed, run by Columbia University. The registered enrollment target is 11 participants, below the 335-participant average among 12 other Lung Transplantation trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00115778, a Phase 2 study of Lung Transplantation and Hypogammaglobulinemia, has completed, sponsored by Columbia University.

COMPLETED
Registry status
Phase 2
Development phase
11 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine if intravenous immunoglobulin (IVIG) can prevent bacterial infections in lung transplant patients with low serum levels of immunoglobulin.

Primary Outcome

The number of events occurring during the treatment period. The data will be presented by the occurrence during the IVIG vs. the placebo treatment period, regardless of the order that the treatment was received. Only the clinically diagnosed bacterial infections will be counted.

Interventions

  • OTHER Placebo
  • DRUG IVIG

Study Locations (1)

New York

  • New York Presbyterian Hospital Lung Transplant Program - New York

Trial Details

FieldValue
Enrollment Target 11 participants
Start Date 2005-06
Est. Completion 2010-08
Phase Phase 2
Columbia University

958 total trials

What the finished NCT00115778 record still lists

NCT00115778 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 335-participant average among 12 other Lung Transplantation trials with a reported enrollment target (97% lower).

The record links to 2 conditions, with Lung Transplantation appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00115778 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT00115778 about?

NCT00115778 is a clinical study titled "Intravenous Immunoglobulin (IVIG) in Lung Transplantation". The purpose of this study is to determine if intravenous immunoglobulin (IVIG) can prevent bacterial infections in lung transplant patients with low serum levels of immunoglobulin.

What is the current status of trial NCT00115778?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2005-06. Estimated completion is 2010-08.

What conditions does trial NCT00115778 study?

This clinical trial studies the following conditions: Lung Transplantation, Hypogammaglobulinemia.

What interventions are being tested in trial NCT00115778?

The interventions under investigation include: Placebo (OTHER), IVIG (DRUG).

Who is sponsoring clinical trial NCT00115778?

This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00115778 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Lung Transplantation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00115778's enrollment target sits among peer trials

11 13th of 12 the lowest of 12 other Lung Transplantation trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Lung Transplantation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03114462 · 11 participants · Phase 1

    Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer

  • NCT06039709 · 11 participants · Phase 1

    Sonodynamic Therapy in Patients With Recurrent GBM

  • NCT06425380 · 11 participants · NA

    Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy

  • NCT06472661 · 11 participants · Early Phase 1

    FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00115778, the US trial registry maintained by the National Library of Medicine. NCT00115778 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.